Insights

Recent Acquisition Expansion The recent $300 million acquisition of Melinta Therapeutics by CorMedix Inc. indicates a significant expansion and validation of Melinta's portfolio in infectious diseases, presenting opportunities to leverage its enhanced resources and broader market reach for sales growth.

Product Launch Opportunities The launch of Kimyrsa and expanded reimbursement for Rezzayo highlights Melinta's focus on innovative therapies for serious illnesses, opening channels for collaboration to promote new products, increase market penetration, and drive sales in critical care segments.

Leadership and Innovation Strategic hires such as CTO Sunitha Lakshminarayanan and Vice President of Medical Affairs Fabrizio Tondolo reinforce Melinta’s commitment to technological advancement and medical expertise, providing a strong foundation for promoting cutting-edge solutions to healthcare providers.

Financial Stability With revenues between $50 million and $100 million and funding of $90 million, Melinta shows a solid financial position that supports expanding sales efforts, exploring new markets, and investing in innovative therapy development.

Strategic Collaborations Partnerships like the exclusive license agreement with Venatorx Pharmaceuticals to commercialize cefepime-taniborbactam demonstrate Melinta’s strategic approach to extending its product portfolio and creating new sales channels in antibiotic markets.

Similar companies to Melinta Therapeutics

Melinta Therapeutics Tech Stack

Melinta Therapeutics uses 8 technology products and services including SiteCatalyst, Power BI, Open Graph, and more. Explore Melinta Therapeutics's tech stack below.

  • SiteCatalyst
    Analytics
  • Power BI
    Business Intelligence
  • Open Graph
    Content Management System
  • Veeva Vault
    Enterprise Content Management
  • JSON-LD
    Javascript Frameworks
  • Vue.js
    Javascript Frameworks
  • Google Charts
    Javascript Graphics
  • Coupa
    Travel And Expense Management

Media & News

Melinta Therapeutics's Email Address Formats

Melinta Therapeutics uses at least 1 format(s):
Melinta Therapeutics Email FormatsExamplePercentage
FLast@melinta.comJDoe@melinta.com
50%
FLast@melinta.comJDoe@melinta.com
50%

Frequently Asked Questions

Where is Melinta Therapeutics's headquarters located?

Minus sign iconPlus sign icon
Melinta Therapeutics's main headquarters is located at 389 Interpace Pkwy, Suite 450 Parsippany, New Jersey 07054, US. The company has employees across 3 continents, including North AmericaEuropeSouth America.

What is Melinta Therapeutics's phone number?

Minus sign iconPlus sign icon
You can contact Melinta Therapeutics's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Melinta Therapeutics's stock symbol?

Minus sign iconPlus sign icon
Melinta Therapeutics is a publicly traded company; the company's stock symbol is MLNTQ.

What is Melinta Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Melinta Therapeutics's official website is melinta.com and has social profiles on LinkedInCrunchbase.

What is Melinta Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign icon
Melinta Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Melinta Therapeutics have currently?

Minus sign iconPlus sign icon
As of November 2025, Melinta Therapeutics has approximately 164 employees across 3 continents, including North AmericaEuropeSouth America. Key team members include CSO: E. D.Chief Human Resources Officer: K. A.Chief Business Officer: J. P.. Explore Melinta Therapeutics's employee directory with LeadIQ.

What industry does Melinta Therapeutics belong to?

Minus sign iconPlus sign icon
Melinta Therapeutics operates in the Biotechnology Research industry.

What technology does Melinta Therapeutics use?

Minus sign iconPlus sign icon
Melinta Therapeutics's tech stack includes SiteCatalystPower BIOpen GraphVeeva VaultJSON-LDVue.jsGoogle ChartsCoupa.

What is Melinta Therapeutics's email format?

Minus sign iconPlus sign icon
Melinta Therapeutics's email format typically follows the pattern of FLast@melinta.com. Find more Melinta Therapeutics email formats with LeadIQ.

How much funding has Melinta Therapeutics raised to date?

Minus sign iconPlus sign icon
As of November 2025, Melinta Therapeutics has raised $90M in funding. The last funding round occurred on Nov 29, 2017 for $90M.

Melinta Therapeutics

Biotechnology ResearchUnited States51-200 Employees

High touch and big impact are trademarks of Melinta. We are nimble and agile without sacrificing our dedication to adding value everywhere we go.

You see, the people of Melinta are believers. Woven into the fiber of our culture is tenacity, brilliance, resilience, excellence and courage. Nothing can weaken our resolve. We take each responsibility seriously, because when we make a move, it matters.

Watch us as we grow. We are the company of the moment and the enterprise of the future. We’re unparalleled in our ability to meet the unmet needs of our patients, and we do so collaboratively. Because we believe the most diverse teams produce the most meaningful impact.

We can’t wait to make legendary strides. Every step counts.

Section iconCompany Overview

Headquarters
389 Interpace Pkwy, Suite 450 Parsippany, New Jersey 07054, US
Phone number
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
MLNTQ
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
51-200

Section iconFunding & Financials

  • $90M

    Melinta Therapeutics has raised a total of $90M of funding over 1 rounds. Their latest funding round was raised on Nov 29, 2017 in the amount of $90Mas a venture funding.

  • $50M$100M

    Melinta Therapeutics's revenue is estimated to be in the range of $50M$100M

Section iconFunding & Financials

  • $90M

    Melinta Therapeutics has raised a total of $90M of funding over 1 rounds. Their latest funding round was raised on Nov 29, 2017 in the amount of $90Mas a venture funding.

  • $50M$100M

    Melinta Therapeutics's revenue is estimated to be in the range of $50M$100M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.